Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 18 years of age~* Rheumatoid arthritis for at least 3 months~* Inadequate response to previous or current treatment with at least one anti-TNF-alpha agent~* Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for the last 4 weeks~* Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline.~* CRP ≥ 0.6 mg/dL using a high-sensitivity assay.~* Positive rheumatoid factor or positive anti-CCP antibody or both.~Exclusion Criteria:~* Rheumatic autoimmune disease or inflammatory joint disease, other than RA~* Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy (Type: EXPERIMENTAL): Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
- Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy (Type: EXPERIMENTAL): Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
- Placebo x 2 IV + Non-Biologic DMARD Therapy (Type: PLACEBO_COMPARATOR): Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD

Based on this trial design, predict the completion outcome and termination type (if applicable).